References
- Johnston, E.; Crawford, J.; Blackwell, S.; , et al. Randomized, dose escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.J. Clin. Oncol. 2000, 18, 2522–2528. [PUBMED], [INFOTRIEVE], [CSA]
- Holmes, F A.; O'Shaughnessy, J A.; Vukelja, S.; , et al. Blinded, randomized multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or III/IV breast cancer.J. Clin. Oncol. 2002, 20, 727–731. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Green, M. A single fixed-dose of pegfilgrastim given once per chemotherapy cycle is as effective as daily filgrastim in the management of neutropenia in high-risk breast cancer.Eur. J. Cancer 2001, 37 (Suppl 6), 146. (abstract 540). [CSA], [CROSSREF]
- Lokich, J. Single-dose granulocyte colony-stimulating factor concomitant with multifractionated dose chemotherapy: a strategy for maintaining dose intensity.Cancer Investig. 1999, 17 (7), 547–550. [CSA]
- Lokich, J. Multifractionated dosing for chemotherapy with flexible cytokine usage: a strategy for optimizing the therapeutic index.Am. J. Clin. Oncol. 2002, 25, 101–102. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Molineux, G.; Kinstler, O.; Briddell, B.; , et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans.Exp. Hematol. 1999, 27, 1724–1734. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]